HuGE Literature Finder
Records
1
-
30
| DPYD polymorphisms c.496A>G, c.2194G>A and c.85T>C and risk of severe adverse drug reactions in patients treated with fluoropyrimidine-based protocols. British journal of clinical pharmacology 2021 Nov . Božina Nada, Bili? Ivan, Ganoci Lana, Šimi?evi? Livija, Pleština Stjepko, Lešnjakovi? Lucija, Trkulja Vladim |
| Dihydropyrimidine dehydrogenase (DPYD) gene c.1627A>G A/G and G/G genotypes are risk factors for lymph node metastasis and distant metastasis of colorectal cancer. Journal of clinical laboratory analysis 2021 Oct e24023. Zeng Juanzi, Wu Heming, Huang Qingyan, Li Jiaquan, Yu Zhikang, Zhong Zhixio |
| Predictive value of clinical toxicities of chemotherapy with fluoropyrimidines and oxaliplatin in colorectal cancer by DPYD and GSTP1 gene polymorphisms. World journal of surgical oncology 2020 Dec 18 (1): 321. Deng Xunwei, Hou Jingyuan, Deng Qiaoting, Zhong Zhixio |
| Effect of drug metabolizing enzymes and transporters in Thai colorectal cancer patients treated with irinotecan-based chemotherapy. Scientific reports 2020 Aug 10 (1): 13486. Atasilp Chalirmporn, Chansriwong Phichai, Sirachainan Ekaphop, Reungwetwattana Thanyanan, Sirilerttrakul Suwannee, Chamnanphon Monpat, Puangpetch Apichaya, Sukasem Chonlaph |
| Germline and Somatic Pharmacogenomics to Refine Rectal Cancer Patients Selection for Neo-Adjuvant Chemoradiotherapy. Frontiers in pharmacology 2020 897. De Mattia Elena, Roncato Rossana, Palazzari Elisa, Toffoli Giuseppe, Cecchin Eri |
| Retracted: Influence of DPYD Genetic Polymorphisms on 5-Fluorouracil Toxicities in Patients with Colorectal Cancer: A Meta-Analysis. Gastroenterology research and practice 2020 2020 9470819. Research And Practice Gastroenterolo |
| Influence of DPYD*9A, DPYD*6 and GSTP1 ile105val Genetic Polymorphisms on Capecitabine and Oxaliplatin (CAPOX) Associated Toxicities in Colorectal Cancer (CRC) Patients. Asian Pacific journal of cancer prevention : APJCP 2019 Oct 20 (10): 3093-3100. Varma K Ashok, Jayanthi M, Dubashi Biswajit, Shewade D |
| The Genotype for DPYD Risk Variants in Patients With Colorectal Cancer and the Related Toxicity Management Costs in Clinical Practice. Clinical pharmacology and therapeutics 2019 Apr 105 (4): 994-1002. Toffoli Giuseppe, Innocenti Federico, Polesel Jerry, De Mattia Elena, Sartor Franca, Dalle Fratte Chiara, Ecca Fabrizio, Dreussi Eva, Palazzari Elisa, Guardascione Michela, Buonadonna Angela, Foltran Luisa, Garziera Marica, Bignucolo Alessia, Nobili Stefania, Mini Enrico, Favaretto Adolfo, Berretta Massimiliano, D'Andrea Mario, De Paoli Antonino, Roncato Rossana, Cecchin Eri |
| DPYD, TYMS and MTHFR Genes Polymorphism Frequencies in a Series of Turkish Colorectal Cancer Patients. Journal of personalized medicine 2018 Dec 8 (4): . Amirfallah Arsalan, Kocal Gizem Calibasi, Unal Olcun Umit, Ellidokuz Hulya, Oztop Ilhan, Basbinar Yasem |
| Early disease relapse in a patient with colorectal cancer who harbors genetic variants of DPYD, TYMS, MTHFR and DHFR after treatment with 5-fluorouracil-based chemotherapy. Drug metabolism and personalized therapy 2018 Sep . Zawiah Mohammed, Yousef Al-Motassem, Kadi Taha, Yousef Mohammed, Majdalawi Khalil, Al-Yacoub Shorouq, Al-Hiary Rasha, Tantawi Dua'a, Mukred Ramzi, Ajaj Abdel Rahm |
| The association of polymorphisms in folate-metabolizing genes with response to adjuvant chemotherapy of colorectal cancer. Cancer chemotherapy and pharmacology 2018 May . Yousef Al-Motassem, Zawiah Mohammed, Al-Yacoub Shorouq, Kadi Taha, Tantawi Dua' A, Al-Ramadhani Hangu |
| DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer. Oncotarget 2018 Jan 9 (8): 7859-7866. Cremolini Chiara, Del Re Marzia, Antoniotti Carlotta, Lonardi Sara, Bergamo Francesca, Loupakis Fotios, Borelli Beatrice, Marmorino Federica, Citi Valentina, Cortesi Enrico, Moretto Roberto, Ronzoni Monica, Tomasello Gianluca, Zaniboni Alberto, Racca Patrizia, Buonadonna Angela, Allegrini Giacomo, Ricci Vincenzo, Di Donato Samantha, Zagonel Vittorina, Boni Luca, Falcone Alfredo, Danesi Roma |
| TYMS 2R3R polymorphism and DPYD [IVS]14+1G>A gene mutation in Mexican colorectal cancer patients. Acta biochimica Polonica 2018 65 (2): 227-234. Gallegos-Arreola Martha Patricia, Zúñiga-González Guillermo Moisés, Sánchez-López Josefina Yoaly, Cruz Alondra Yeraldi Naranjo, Peralta-Leal Valeria, Figuera Luis Eduardo, Puebla-Pérez Ana María, Ronquillo-Carreón Carlos Alberto, Puebla-Mora Ana Gracie |
| DPYD genotype and haplotype analysis and colorectal cancer susceptibility in a case-control study from Slovakia. General physiology and biophysics 2017 Dec 36 (5): 557-563. Matáková Tatiana, Halašová Erika, Škovierová Henrieta, Dzian Anton, Dobrota Dušan, Škere?ová Már |
| DPYD*2A and MTHFR C677T predict toxicity and efficacy, respectively, in patients on chemotherapy with 5-fluorouracil for colorectal cancer. Cancer chemotherapy and pharmacology 2017 Nov . Nahid Noor Ahmed, Apu Mohd Nazmul Hasan, Islam Md Reazul, Shabnaz Samia, Chowdhury Surid Mohammad, Ahmed Maizbha Uddin, Nahar Zabun, Islam Md Siddiqul, Islam Mohammad Safiqul, Hasnat Ab |
| Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis. BMC cancer 2017 Jun 17 (1): 437. Liu Dan, Li Jian, Gao Jing, Li Yanyan, Yang Rui, Shen L |
| Identification of new SNPs associated with severe toxicity to capecitabine. Pharmacological research 2017 Mar 120 133-137. Pellicer Marta, García-González Xandra, García María I, Robles Luis, Grávalos Cristina, García-Alfonso Pilar, Pachón Vanessa, Longo Federico, Martínez Virginia, Blanco Carolina, Iglesias Irene, Sanjurjo María, López-Fernández Luis |
| 5-Fluorouracil degradation rate could predict toxicity in stages II-III colorectal cancer patients undergoing adjuvant FOLFOX. Anti-cancer drugs 2016 Nov . Onesti Concetta E, Botticelli Andrea, La Torre Marco, Borro Marina, Gentile Giovanna, Romiti Adriana, Lionetto Luana, Petremolo Antonella, Occhipinti Mario, Roberto Michela, Falcone Rosa, Simmaco Maurizio, Marchetti Paolo, Mazzuca Federi |
| DPYD Genotyping to Predict Adverse Events Following Treatment With Fluorouracil-Based Adjuvant Chemotherapy in Patients With Stage III Colon Cancer: A Secondary Analysis of the PETACC-8 Randomized Clinical Trial. JAMA oncology 2016 Jan . Boige Valérie, Vincent Marc, Alexandre Philippe, Tejpar Sabine, Landolfi Stefania, Le Malicot Karine, Greil Richard, Cuyle Pieter Jan, Yilmaz Mette, Faroux Roger, Matzdorff Axel, Salazar Ramon, Lepage Côme, Taieb Julien, Laurent-Puig Pier |
| DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan. British journal of clinical pharmacology 2015 Sep 80 (3): 581-8. Falvella Felicia Stefania, Cheli Stefania, Martinetti Antonia, Mazzali Cristina, Iacovelli Roberto, Maggi Claudia, Gariboldi Manuela, Pierotti Marco Alessandro, Di Bartolomeo Maria, Sottotetti Elisa, Mennitto Roberta, Bossi Ilaria, de Braud Filippo, Clementi Emilio, Pietrantonio Filip |
| Correlation between DPYD gene variation and KRAS wild type status in colorectal cancer. Journal of clinical pathology 2015 Aug . Kleist Britta, Kempa Marcel, Meurer Thuja, Poetsch Micae |
| Frequent intragenic rearrangements of DPYD in colorectal tumours. The pharmacogenomics journal 2015 Jun 15 (3): 211-8. van Kuilenburg A B P, Etienne-Grimaldi M-C, Mahamat A, Meijer J, Laurent-Puig P, Olschwang S, Gaub M-P, Hennekam R C M, Benchimol D, Houry S, Letoublon C, Gilly F-N, Pezet D, Andre T, Faucheron J-L, Abderrahim-Ferkoune A, Vijzelaar R, Pradere B, Milano |
| Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy. Cancer chemotherapy and pharmacology 2015 Apr 75 (4): 763-72. Joerger M, Huitema A D R, Boot H, Cats A, Doodeman V D, Smits P H M, Vainchtein L, Rosing H, Meijerman I, Zueger M, Meulendijks D, Cerny T D, Beijnen J H, Schellens J H |
| A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS. Gut 2015 Jan 64 (1): 111-20. Rosmarin Dan, Palles Claire, Pagnamenta Alistair, Kaur Kulvinder, Pita Guillermo, Martin Miguel, Domingo Enric, Jones Angela, Howarth Kimberley, Freeman-Mills Luke, Johnstone Elaine, Wang Haitao, Love Sharon, Scudder Claire, Julier Patrick, Fernández-Rozadilla Ceres, Ruiz-Ponte Clara, Carracedo Angel, Castellvi-Bel Sergi, Castells Antoni, Gonzalez-Neira Anna, Taylor Jenny, Kerr Rachel, Kerr David, Tomlinson I |
| Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2014 Apr 32 (10): 1031-9. Rosmarin Dan, Palles Claire, Church David, Domingo Enric, Jones Angela, Johnstone Elaine, Wang Haitao, Love Sharon, Julier Patrick, Scudder Claire, Nicholson George, Gonzalez-Neira Anna, Martin Miguel, Sargent Daniel, Green Erin, McLeod Howard, Zanger Ulrich M, Schwab Matthias, Braun Michael, Seymour Matthew, Thompson Lindsay, Lacas Benjamin, Boige Valérie, Ribelles Nuria, Afzal Shoaib, Enghusen Henrik, Jensen Søren Astrup, Etienne-Grimaldi Marie-Christine, Milano Gérard, Wadelius Mia, Glimelius Bengt, Garmo Hans, Gusella Milena, Lecomte Thierry, Laurent-Puig Pierre, Martinez-Balibrea Eva, Sharma Rohini, Garcia-Foncillas Jesus, Kleibl Zdenek, Morel Alain, Pignon Jean-Pierre, Midgley Rachel, Kerr David, Tomlinson I |
| Influence of DPYD Genetic Polymorphisms on 5-Fluorouracil Toxicities in Patients with Colorectal Cancer: A Meta-Analysis. Gastroenterology research and practice 2014 2014 827989. Li Qiang, Liu Ying, Zhang Hong-Mei, Huang Yin-Peng, Wang Tian-Yi, Li Dong-Sheng, Sun Hong-Z |
| Evaluating predictive pharmacogenetic signatures of adverse events in colorectal cancer patients treated with fluoropyrimidines. PloS one 2013 8 (10): e78053. Jennings Barbara A, Loke Yoon K, Skinner Jane, Keane Melanie, Chu Gavin S, Turner Richard, Epurescu Daniel, Barrett Ann, Willis Gav |
| [Validation of genetic polymorphisms associated to the toxicity of chemotherapy in colorectal cancer patients]. Farmacia hospitalaria : órgano oficial de expresión científica de la Sociedad Española de Farmacia Hospitalaria 0 38 (4): 283-90. Cortejoso L, García M I, García-Alfonso P, Grávalos C, Robles L, González-Haba E, Sanjurjo M, López-Fernández L |
| Degradation Rate of 5-Fluorouracil in Metastatic Colorectal Cancer: A New Predictive Outcome Biomarker? PloS one 0 11 (9): e0163105. Botticelli Andrea, Borro Marina, Onesti Concetta Elisa, Strigari Lidia, Gentile Giovanna, Cerbelli Bruna, Romiti Adriana, Occhipinti Mario, Sebastiani Claudia, Lionetto Luana, Marchetti Luca, Simmaco Maurizio, Marchetti Paolo, Mazzuca Federi |
| DPYD*2A/*5A/*9A and UGT1A1*6/*28 polymorphisms in Chinese colorectal cancer patients. Journal of cancer research and therapeutics 0 12 (2): 782-6. Li Guo-Yin, Duan Jian-Feng, Li Wan-Jun, Liu T |
- Page last reviewed:Jul 25, 2022
- Page last updated:Aug 18, 2022
- Content source: